Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis

Janka, Eszter Anna; Várvölgyi, Tünde; Sipos, Zoltán; Soós, Alexandra; Hegyi, Péter; Kiss, Szabolcs; Dembrovszky, Fanni; Csupor, Dezső; Keringer, Patrik; Pécsi, Dániel; Solymár, Margit; Emri, Gabriella

doi:10.3389/fonc.2021.772165

Cited by 13 publications

(18 citation statements)

References 73 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these proteins, two markers from the S100 family (EN-RAGE and S100A11) displayed particularly strong associations closer to diagnosis. Proteins in the S100 family are implicated in tumorigenesis and cancer progression through different mechanisms of inflammation, cell differentiation, and cell proliferation 31 , and have been proposed as biomarkers for prognosis of melanoma 32,33 . These observations suggest that the risk associations are likely to reflect a somatic response to (or the direct action of) a subclinical lung tumor, rather than differences in tobacco exposure.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The blood proteome of imminent lung cancer diagnosis

Albanes,

Alcala,

Alcala

et al. 2023

Nat Commun

View full text Add to dashboard Cite

Identification of risk biomarkers may enhance early detection of smoking-related lung cancer. We measured between 392 and 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within six prospective cohorts from the US, Europe, Singapore, and Australia. We identify 36 proteins with independently reproducible associations with risk of imminent lung cancer diagnosis (all p < 4 × 10−5). These include a few markers (e.g. CA-125/MUC-16 and CEACAM5/CEA) that have previously been reported in studies using pre-diagnostic blood samples for lung cancer. The 36 proteins include several growth factors (e.g. HGF, IGFBP-1, IGFP-2), tumor necrosis factor-receptors (e.g. TNFRSF6B, TNFRSF13B), and chemokines and cytokines (e.g. CXL17, GDF-15, SCF). The odds ratio per standard deviation range from 1.31 for IGFBP-1 (95% CI: 1.17–1.47) to 2.43 for CEACAM5 (95% CI: 2.04–2.89). We map the 36 proteins to the hallmarks of cancer and find that activation of invasion and metastasis, proliferative signaling, tumor-promoting inflammation, and angiogenesis are most frequently implicated.

show abstract

Section: Discussionmentioning

confidence: 99%

“…32 These authors contributed equally: Karine Alcala, Florence Guida, Mikael Johansson, Karl Smith-Byrne, Victoria Stevens, Hana Zahed. 33 These authors jointly supervised this work: Mattias Johansson, Hilary A. Robbins.…”

Section: Reporting Summarymentioning

confidence: 99%

The blood proteome of imminent lung cancer diagnosis

Albanes,

Alcala,

Alcala

et al. 2023

Nat Commun

View full text Add to dashboard Cite

show abstract

“…Therefore, the serum lactate dehydrogenase level in cancer patients increases, and lactate dehydrogenase is related to the prognosis of various malignant tumors [ 13 , 14 ]. Previous studies have shown that LDH is an independent risk factor for prognosis MM cases, and the serum LDH level in MM cases is high [ 15 , 16 ]. In addition, it has been reported that serum LDH levels have shown varying degrees of elevation, indicating anaerobic glycolysis in tissues before imaging manifestations in tumor cases.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Lactate Dehydrogenase, Melanoma Inhibitory Protein, and S-100B Protein in Patients with Malignant Melanoma

Fan

Liu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This investigation probed the prognostic potential for lactate dehydrogenase (LDH), melanoma inhibitory activity protein (MIA), and S-100B protein in cases of malignant melanoma. Methods. 84 cases were segregated into effective cohort (n = 64) and ineffective cohort (n = 20) depending on clinical efficacy. The cases were followed up for three years and segregated into mortality cohort (n = 29) and survival cohort (n = 55) depending upon 3-year survival. Serum LDH, MIA, and S-100B levels were compared across the effective and ineffective cohorts. Serum LDH, MIA, and S-100B levels in cases of different clinical stages were comparatively analyzed, with correlations of these indicators with the clinical stage being evaluated. ROC evaluated the prognostic potential of serum LDH, MIA, and S-100B. Cases were segregated into the high-level and low-level cohorts according to serum LDH, MIA, and S-100B levels, and the survival rates of cases were compared. Results. The levels of LDH, MIA, and S-100B in the effective cohort were significantly lower than those in the ineffective cohort. The AUC value of the composite indicator of serum LDH, MIA, and S-100B for effectiveness evaluation was (0.839). Serum LDH, MIA, and S-100B levels were positively linked to the clinical stage. AUC value of the composite indicator of serum LDH, MIA, and S-100B for prognosis evaluation prediction (0.942) was elevated compared to LDH (0.632), MIA (0.732), or S-100B (0.828) alone. Survival rate of cases of LDH ≥30.56 mg/L (57.14%, 32/56) was lower than that of cases of LDH <30.56 mg/L (82.14%, 23/28) (log-rank χ2 = 4.672, P < 0.05 ). The survival rate of MIA ≥5.34 ng/mL cases was lower than that of MIA <5.34 ng/mL cases. The survival rate of cases of S-100B ≥ 1.03ug/L was lower than that of S-100B < 1.03ug/L. Conclusion. Serum LDH, MIA, and S-100B protein levels are linked to the clinical stage. The lactate dehydrogenase, melanoma inhibitory protein, and S-100B protein are of good clinical effectiveness and have the prognostic potential for cases of malignant melanoma.

show abstract

“…Proteins in the S100 family have previously been proposed as biomarkers for prognosis of malignant melanoma. 48,49 We found limited evidence for heterogeneity in associations for most of the 36 markers when stratifying by smoking status, and little impact of additional adjustment for smoking characteristics. This suggests that the associations reflect a somatic response to (or the direct action of) a subclinical lung tumour, rather than differences in tobacco exposure.…”

Section: Epidemiological Properties Of Identified Proteinsmentioning

confidence: 75%

“…Proteins in the S100 family have previously been proposed as biomarkers for prognosis of malignant melanoma. 48,49…”

Section: Discussionmentioning

confidence: 99%

The Blood Proteome of Imminent Lung Cancer Diagnosis

Alcala

Guida

Johansson

et al. 2022

Preprint

View full text Add to dashboard Cite

Identification of novel risk biomarkers may enhance early detection of smoking-related lung cancer. We measured 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within six prospective cohorts from the US, Europe, Singapore, and Australia. We identified 36 proteins with replicable associations with risk of imminent lung cancer diagnosis (all p<4x10-5). These included several documented tumor markers (e.g. CA-125/MUC-16 and CEACAM5/CEA) but most had not been previously reported. The 36 proteins included several growth factors (e.g. HGF, IGFBP-1, IGFP-2), tumor necrosis factor-receptors (e.g. TNFRSF6B, TNFRSF13B), and chemokines and cytokines (e.g. CXL17, GDF-15, SCF). The odds ratio per standard deviation ranged from 1.31 for IGFBP-1 (95% CI: 1.17-1.47) to 2.43 for CEACAM5 (95% CI: 2.04-2.89). We mapped the 36 proteins to the hallmarks of cancer and found that proliferative signaling, tumor-promoting inflammation, and activation of invasion and metastasis were most frequently implicated.

show abstract

Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis

Cited by 13 publications

References 73 publications

The blood proteome of imminent lung cancer diagnosis

The blood proteome of imminent lung cancer diagnosis

Prognostic Value of Lactate Dehydrogenase, Melanoma Inhibitory Protein, and S-100B Protein in Patients with Malignant Melanoma

The Blood Proteome of Imminent Lung Cancer Diagnosis

Contact Info

Product

Resources

About